Bert Kinsey, PhD, PharmD

Bert Kinsey, PhD, PharmD

Bert joined Pappas Capital in 2020, and brings significant experience in translational biomedical research and biotechnology equity research. Prior to joining Pappas, he spent two years at RBC Capital Markets in New York City as a Senior Associate on an Institutional Investor-ranked equity research team covering large-, mid- and small-cap biotech companies. At RBC he gained experience building and maintaining financial models, vetting public and private biotechs to support investment banking, and conducted clinical and commercial diligence to shape investment theses. Prior to RBC, Bert was Associate Professor of Medicine at the University of Virginia (UVA) where he established an independent research laboratory investigating the role of the immune system in different forms of kidney disease. Throughout his 10 years at UVA, his laboratory was consistently funded by the NIH, including R01, R21, K01 and F32 grants focused on the role of regulatory T cells in acute kidney injury. His academic experience included in vitro and in vivo preclinical experimentation, as well as translational clinical research in cardiac surgery patients.

Education:

Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)

 

Cookie Yu, PhD

 

Cookie comes from a multidisciplinary scientific background and is actively involved in evaluating investment opportunities for Pappas Capital. Prior to joining Pappas in 2019, she worked as an analyst at M. Ventures, a subsidiary of Merck KGaA, in Darmstadt, Germany. During her time at M. Ventures, Cookie performed market analysis in a wide range of life science and therapeutic areas for venture opportunities, in alignment with global corporate strategies. She also served on the financial team and received training in venture fund controlling.

Before becoming a venture capitalist, Cookie was a researcher at Stony Brook University, where she developed platform technologies in cardiac optogenetics and single cell analysis. In 2016, Cookie was selected as a recipient of the Program for Excellence in Science Award from AAAS. During her time at Stony Brook, Cookie also worked with the New York State Center for Biotechnology on assessing the commercial potential of discovery-stage programs and formulating their development and financing strategies. She supplemented her life science technical expertise with financial understanding by passing the CFA Level I exam. When she is not scouting new technologies, Cookie enjoys foraging wild mushrooms in the forests, traveling, and Latin dancing.

Education:

Stony Brook University  (PhD in Biomedical Engineering)